Literature DB >> 19931193

Genomic and personalized medicine: foundations and applications.

Geoffrey S Ginsburg1, Huntington F Willard.   

Abstract

The last decade has witnessed a steady embrace of genomic and personalized medicine by senior government officials, industry leadership, health care providers, and the public. Genomic medicine, which is the use of information from genomes and their derivatives (RNA, proteins, and metabolites) to guide medical decision making-is a key component of personalized medicine, which is a rapidly advancing field of health care that is informed by each person's unique clinical, genetic, genomic, and environmental information. As medicine begins to embrace genomic tools that enable more precise prediction and treatment disease, which include "whole genome" interrogation of sequence variation, transcription, proteins, and metabolites, the fundamentals of genomic and personalized medicine will require the development, standardization, and integration of several important tools into health systems and clinical workflows. These tools include health risk assessment, family health history, and clinical decision support for complex risk and predictive information. Together with genomic information, these tools will enable a paradigm shift to a comprehensive approach that will identify individual risks and guide clinical management and decision making, all of which form the basis for a more informed and effective approach to patient care. DNA-based risk assessment for common complex disease, molecular signatures for cancer diagnosis and prognosis, and genome-guided therapy and dose selection are just among the few important examples for which genome information has already enabled personalized health care along the continuum from health to disease. In addition, information from individual genomes, which is a fast-moving area of technological development, is spawning a social and information revolution among consumers that will undoubtedly affect health care decision making. Although these and other scientific findings are making their way from the genome to the clinic, the full application of genomic and personalized medicine in health care will require dramatic changes in regulatory and reimbursement policies as well as legislative protections for privacy for system-wide adoption. Thus, there are challenges from both a scientific and a policy perspective to personalized health care; however, they will be confronted and solved with the certainty that the science behind genomic medicine is sound and the practice of medicine that it informs is evidence based.

Entities:  

Mesh:

Year:  2009        PMID: 19931193     DOI: 10.1016/j.trsl.2009.09.005

Source DB:  PubMed          Journal:  Transl Res        ISSN: 1878-1810            Impact factor:   7.012


  142 in total

1.  Practices and perspectives on building integrated data repositories: results from a 2010 CTSA survey.

Authors:  Sandra L MacKenzie; Matt C Wyatt; Robert Schuff; Jessica D Tenenbaum; Nick Anderson
Journal:  J Am Med Inform Assoc       Date:  2012-03-21       Impact factor: 4.497

2.  Navigating the road to personalized medicine: can we believe?

Authors:  Gideon M Hirschfield; Christopher I Amos; Katherine A Siminovitch
Journal:  CMAJ       Date:  2010-04-06       Impact factor: 8.262

Review 3.  Coping styles and behavioural flexibility: towards underlying mechanisms.

Authors:  Caroline M Coppens; Sietse F de Boer; Jaap M Koolhaas
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2010-12-27       Impact factor: 6.237

4.  Coverage policy development for personalized medicine: private payer perspectives on developing policy for the 21-gene assay.

Authors:  Julia R Trosman; Stephanie L Van Bebber; Kathryn A Phillips
Journal:  J Oncol Pract       Date:  2010-09       Impact factor: 3.840

Review 5.  Cost effectiveness of pharmacogenomics: a critical and systematic review.

Authors:  William B Wong; Josh J Carlson; Rahber Thariani; David L Veenstra
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 6.  Have genomic discoveries in inflammatory bowel disease translated into clinical progress?

Authors:  Adam V Weizman; Mark S Silverberg
Journal:  Curr Gastroenterol Rep       Date:  2012-04

7.  Relationship between endogenous opioid function and opioid analgesic adverse effects.

Authors:  Rajnish K Gupta; Stephen Bruehl; John W Burns; Asokumar Buvanendran; Melissa Chont; Erik Schuster; Christopher R France
Journal:  Reg Anesth Pain Med       Date:  2014 May-Jun       Impact factor: 6.288

Review 8.  Multimodal therapies for muscle-invasive urothelial carcinoma of the bladder.

Authors:  Kirk A Keegan; Matthew J Resnick; Peter E Clark
Journal:  Curr Opin Oncol       Date:  2012-05       Impact factor: 3.645

Review 9.  Toward exercise as personalized medicine.

Authors:  Thomas W Buford; Michael D Roberts; Timothy S Church
Journal:  Sports Med       Date:  2013-03       Impact factor: 11.136

10.  Prostate cancer risk assessment tools in an unscreened population.

Authors:  D J Lundon; B D Kelly; R Foley; S Loeb; J M Fitzpatrick; R W G Watson; E Rogers; G C Durkan; K Walsh
Journal:  World J Urol       Date:  2014-08-05       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.